A clinical drug candidate that triggers non-apoptotic cancer cell death
Preprint
- 11 February 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Small molecules that induce non-apoptotic cell death are of fundamental mechanistic interest and may be useful to treat certain cancers. Here, we report that tegavivint, a drug candidate undergoing human clinical trials, can activate a unique mechanism of non-apoptotic cell death in sarcomas and other cancer cells. This lethal mechanism is distinct from ferroptosis, necroptosis and pyroptosis and requires the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR). TECR is canonically involved in the synthesis of very long chain fatty acids but appears to promote non-apoptotic cell death in response to CIL56 and tegavivint via the synthesis of the saturated long-chain fatty acid palmitate. These findings outline a lipid-dependent non-apoptotic cell death mechanism that can be induced by a drug candidate currently being tested in humans.Keywords
All Related Versions
- Version 1, 2025-02-11, Research Square
- Published version: Nature Chemical Biology, 21 (12), 1873.
This publication has 73 references indexed in Scilit:
- Very-long-chain fatty acids are crucial to neuronal polarity by providing sphingolipids to lipid raftsCell Reports, 2023
- CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosisCancer Cell, 2023
- Surveying the landscape of emerging and understudied cell death mechanismsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2023
- ATP6V0D1 promotes alkaliptosis by blocking STAT3-mediated lysosomal pH homeostasisCell Reports, 2022
- Kinetic Heterogeneity of Cancer Cell Fractional KillingCell Reports, 2020
- The Coming Decade of Cell Death Research: Five RiddlesCell, 2019
- Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell StateCell Chemical Biology, 2019
- Defining a Cancer Dependency MapCell, 2017
- Regulation of Ferroptotic Cancer Cell Death by GPX4Cell, 2014
- 2-Bromopalmitoyl-CoA and 2-bromopalmitate: Promiscuous inhibitors of membrane-bound enzymesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992